Clinical trials: Streptococcus Pneumoniae Vaccines
Meningococcal Meningitis, Measles
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers.
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00422292
- Testing
- Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,664 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infection
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
The proposed phase IIb randomized, open label, dose ranging, safety and immunogenicity study will evaluate two different doses of 13-valent pneumococcal conjugate vaccine (PCV13) in two groups of participants (55 through 74 years…
- Trial name
- NCT01654263
- Testing
- Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
- Where
- 7 sites in United States
- Volunteers
- 884 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Measles, Mumps
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00109343
- Testing
- Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Volunteers
- 1,027 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COPD, Pneumonia
Burden of Hospitalized Pneumonia in Korea COPD Population
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. By 2030, COPD is expected to be the fourth main cause of death.
- Conditions
- COPD, Pneumonia, Pneumococcal Vaccine
- Trial name
- COPDCAP (NCT03046134)
- Testing
- PCV13
- Where
- 4 sites in South Korea
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Chung-Ang University Hospital
Pneumococcal Vaccine
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
- Trial name
- NCT06337643
- Testing
- MVX01
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Infections, Streptococcal
Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of a booster (fourth) dose of pneumococcal vaccine GSK1024850A when co-administered with Hiberix at 12-18 months of age, in children primed…
- Trial name
- NCT00911144
- Testing
- GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A), Wyeth-Lederle's Prevenar™, GSK Biologicals' Hiberix™
- Where
- 14 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Vaccines
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC)…
- Trial name
- NCT01392378
- Testing
- 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, Paracetamol
- Where
- 14 sites in Poland
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Pneumococcal Disease
7-valent Pneumococcal Conjugated Vaccination
Hypothesis: the efficacy of 2 doses 7-valent PCV is equivalent to 1 dose 7-valent PCV.
- Trial name
- PCV (NCT00885625)
- Testing
- 7-valent pneumococcal conjugated vaccine
- Where
- Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago.
- Trial name
- NCT00546572
- Testing
- 13 valent Pneumococcal Conjugate Vaccine, 23vPS
- Where
- 58 sites in United States, Sweden
- Volunteers
- 938 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Immunization
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate…
- Trial name
- NCT06824194
- Testing
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
- Where
- 132 sites in United States, Honduras and 4 more
- Volunteers
- 2,360 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pneumococcal Infections
Pneumococcal Vaccination of Fiji Infants
Pneumonia is the most common reason for admission of Fijian children to hospitals. The most common germ causing pneumonia is "streptococcus pneumoniae." It is a common cause of meningitis (infection around the brain and spinal…
- Trial name
- NCT00170612
- Testing
- Pneumovax 23, Prevnar
- Where
- Fiji
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Pneumonia, Pneumococcal
Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)
To explore a further dimension of susceptibility to disease, the investigators tested the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that…
- Trial name
- NCT03460730
- Testing
- Pneumovax
- Where
- Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Infants' Family Decide Baby's Vaccine
Using "SDM With PDAs" to Help Infant Family to Decide the Third Primary Dosing Pneumococcal Conjugate Vaccine
Pneumococcal infection is one the common infectious disease in the world. Pneumococcal conjugate vaccine may decrease the incidence of pneumococcal infection.
- Trial name
- NCT05578144
- Testing
- Patients Decision Aids (PDA)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Healthy Volunteers
Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23
The research objective is to evaluate lot-to-lot consistency and immune persistence of three commercial batches of 23 valent pneumococcal polysaccharide vaccine.
- Trial name
- NCT06314867
- Testing
- 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1), 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2), 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)
- Where
- China
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Pneumonia
PCV10 Reactogenicity and Immunogenicity Study - Malindi
The World Health Organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (PCV) into their routine immunization schedules.
- Trial name
- PRISM (NCT01028326)
- Testing
- PCV10 and DTaP, hepatitis A vaccine, DTaP, PCV10
- Where
- Kenya
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Infections, Streptococcal
Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose
This primary purpose of this study is the evaluation of the immunological persistence following completion of the 3-dose primary vaccination course with either a clinical or a commercial lot of pneumococcal conjugate vaccine…
- Trial name
- NCT01119625
- Testing
- Pneumococcal vaccine GSK1024850A, Infanrix-IPV/Hib
- Where
- 3 sites in Singapore
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asplenia
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent.
- Trial name
- NCT02232191
- Testing
- Pneumovax-23
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of California, Davis
Haemophilus Influenzae, Streptococcus Pneumoniae
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease.
- Trial name
- NCT00849069
- Testing
- GSK2231395A, TwinrixTM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline